Multiple Sclerosis is an autoimmune disease, causing chronic and disabling effect on the central nervous system, including numbness, pain, weakness, fatigue and numbness.
In 2008 a study of 40 patients showed improvement in spasticity after 6 months.
Futher studies have shown that low dose naltrexone did not reduce the need for other MS medicines however 4.5mg given in a 60 MS patient study over 8 weeks improved mental health quality and other life measures with no adverse events.
There is significant clinical evidence that LDN slows down MS progression and reduces MS relapse.
Standard dosing applies when using LDN for MS.